Tirbanibulin

What Is Tirbanibulin?

• Tirbanibulin (KLISYRI) is a microtubule inhibitor indicated for the topical treatment of actinic keratosis of the face or scalp.

What are the uses of this medicine?

Tirbanibulin (KLISYRI) is indicated for the topical treatment of actinic keratosis on the face or scalp.

How does this medicine work?

• Tirbanibulin is a microtubule inhibitor.
• The mechanism of action of KLISYRI for the topical treatment of actinic keratosis is unknown.
• An orally bioavailable small molecule Src kinase inhibitor with potential antineoplastic activity.
• Unlike other Src kinase inhibitors which bind to the ATP-binding site, tirbanibulin specifically binds to the peptide substrate binding site of Src kinase; inhibition of kinase activity may result in the inhibition of primary tumor growth and the suppression of metastasis.
• Src tyrosine kinases are upregulated in many tumor cells and play important roles in tumor cell proliferation and metastasis.

Who Should Not Use this medicine ?

• This medicine have no usage limitations

Is this medicine FDA approved?

• It was approved for use in the United States in 2020.

How should this medicine be used?

• For topical use only; not for oral or ophthalmic use.
• Apply sufficient amount of KLISYRI to evenly cover up to 25 cm2 treatment field on the face or scalp once daily for 5 consecutive days using 1 single-dose packet per application.
• Wash hands immediately with soap and water after application.
• Avoid washing and touching the treated area for approximately 8 hours after application of KLISYRI.
• Following this time, the area may be washed with a mild soap.
• Avoid transfer of KLISYRI to the periocular area.
• Avoid application near and around the mouth and lips.

What are the dosage forms and brand names of this medicine?

This medicine is available in fallowing doasage form:

• As an ointment: 1% white to off-white ointment in a single-dose packet (2.5 mg tirbanibulin in 250 mg).

This medicine is available in fallowing brand namesː

• KLISYRI

What side effects can this medication cause?

Common possible side effects of this medicine include:

• local skin reactions
• application site pruritus
• application site pain

What special precautions should I follow?

• Avoid transfer of the drug into the eyes and to the periocular area during and after application.
• Wash hands immediately after application.
• If accidental exposure occurs, instruct patient to flush eyes with water and seek medical care as soon as possible.
• Local skin reactions, including severe reactions (erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation and erosion/ulceration) in the treated area can occur after topical application of KLISYRI.
• Avoid use until skin is healed from any previous drug, procedure, or surgical treatment.

What to do in case of emergency/overdose?

• Overdose of this medicine could cause an increase in incidence and severity of local skin reactions.

Can this medicine be used in pregnancy?

• There are no available data with KLISYRI use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes.

Can this medicine be used in children?

• It is not known if KLISYRI is safe and effective in children less than 18 years of age.

What should I know about storage and disposal of this medication?

• Store at room temperature between 68°F to 77°F (20°C to 25°C) .
• Do not refrigerate or freeze.
• Safely throw away used KLISYRI packets in household trash.
• Keep KLISYRI and all medicines out of the reach of children.

This article is a stub. You can help WikiMD by registering to expand it. Editing is available only to registered and verified users. WikiMD is a comprehensive, free health & wellness encyclopedia.

• Dailymed label info on Tirbanibulin
• FDA Tirbanibulin

Tirbanibulin Resources
Latest articles Most recent articles Ongoing trials	Wikipedia